ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1705

Deep Phenotyping Characterization of Peripheral Natural Killer Cells Reveals Impaired Cytotoxicity and Exhaustion During VEXAS Syndrome

Paul Breillat1, Carbone Francesco2, Possémé Céline3, Marie Templé4, Aurélien Corneau5, Marine Luka2, Camille Gobeaux6, Rodéreau Outh7, Estibaliz Lazaro8, Guillaume Le Guenno9, François Lifermann10, Marie Berleur11, Melchior Le Mene4, Chloé Friedrich4, Cédric Lenormand12, Thierry Weitten13, Vivien Guillotin14, Barbara Burroni6, Jeremy Boussier15, Lise Willems6, Léa Dionet16, Tharaux Pierre-Louis16, Darragh duffy17, Mickael Ménager18, Olivier Kosmider4 and Benjamin Terrier19, 1Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM U970, Université de Paris, PARIS, France, 2Institut Imagine, Paris, France,, Paris, France, 3Institut Pasteur, Paris, France, Paris, France, 4Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France, Paris, France, 5Sorbonne Université, Paris, France, 6Cochin Hospital, Paris, France, Paris, France, 7CH, Perpignan, France,, Perpignan, France, 8Bordeaux University Hospital, Pessac, France, 9CHU, Clermont-Ferrand, France,, Clermont-Ferrand, France, 10Dax Hospital, Dax, France, Dax, France, 11CHU Bichat, Paris France, Paris, France, 12CHRU, Strasbourg, France, Strasbourg, France, 13CHIGAS, Gap, France, Gap, France, 14CHU Bordeaux, Bordeaux, France, Bordeaux, France, 15Sorbonne University, Paris, France, 16Paris Cardiovascular Research Center, INSERM U970, Paris, France, 17Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, 18Institut Imagine, Paris, France, Paris, France, 19Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Infection, Natural Killer Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a severe auto-inflammatory disorder associated with acquired mutations in the UBA1 gene that occur in hematopoietic stem cells and persist in peripheral mature myeloid cells, but also, as recently described, in natural killer (NK) cells. VEXAS syndrome is associated with a high incidence of severe infections, especially with opportunistic pathogens. We hypothesized that the NK cell immune response may be impaired in VEXAS syndrome.

Methods: This was a non-interventional study in the setting of a local biological samples collected in routine care. A written informed consent was collected for all participants. Patients included were adults with severe autoinflammatory disease with (VEXAS) or without (VEXAS-like) UBA1 somatic mutations. We compared with gender-matched healthy controls (HCs). We performed an integrated immune analysis of peripheral NK cells including multiparameter phenotyping using CyTOF, single-cell gene expression analyses, cytokine profiling and whole blood cytokine response to Toll-like receptor (TLR) agonists challenge using the TrueCulture system.

Results: Forty-two VEXAS patients, 20 VEXAS-like and 36 HCs were included in the CyTOF analysis. Peripheral NK cells from UBA1-mutated individuals were quantitatively impaired with a median (IQR) count of 49/mm3 (19.5-122) vs 217 (138-346) in HCs (p< 0.0001) and 192 (135-276) in VEXAS-like, (p=0.0004). NK cells from VEXAS patients exhibited features of impaired cytotoxic capacity with decreased CD8a expression compared to HCs (58.3% vs 26.9% p< 0.0001), exhaustion with increased PD-1 (59.6% vs 29% in HCs p< 0.0001 and 44.2% in VEXAS-like p=0.03) and Tim3 expression (57% vs 27% in HCs p< 0.0001), and had aberrant CCR4 and CCR6 expression. VEXAS NK cells also had decreased CXCR3 expression (7.1% in VEXAS vs. 14.6% in HCs p=0.0002 and 14.2% in VEXAS-like p=0.001), which play a role in NK cell recruitment to tissues and promotes NK cell-mediated cytotoxicity.

Single-cell gene expression analysis revealed increased inflammatory signatures (including NFkB, TNFa, IL-6 and IL-1 signaling), unfold protein response, apoptosis and P53 signatures in NK cells from VEXAS patients. They also showed decreased cytotoxicity and Granzyme A-mediated apoptosis signatures, as well as IL-2 and IFN-y production signatures.

Peripheral blood cytokine levels showed similar results between the 3 groups for IL-2, IL-12, IL-15, IFN-y and granzyme B. In contrast, circulating levels of PDL1 were significantly increased in VEXAS patients with a median (IQR) of 135 pg/mL (115-166) vs 81 (67-91), p=0.0006 in HCs and 110 (87-140) in VEXAS-Like, p=0.02).

TruCulture assays shows impaired cytokine (IL-2, IL-15 and IFN-y) and Granzyme B production after whole blood stimulation with TLR4 (LPS), TLR7/TLR8 (R8478) and TLR3 (polyl:C) agonists.

Conclusion: Our results suggest that peripheral NK cells from VEXAS patients exhibit an exhausted phenotype with impaired cytotoxicity. This may play a role in the increased risk of severe infections associated with VEXAS syndrome.


Disclosures: P. Breillat: None; C. Francesco: None; P. Céline: None; M. Templé: None; A. Corneau: None; M. Luka: None; C. Gobeaux: None; R. Outh: None; E. Lazaro: None; G. Le Guenno: None; F. Lifermann: None; M. Berleur: None; M. Le Mene: None; C. Friedrich: None; C. Lenormand: None; T. Weitten: None; V. Guillotin: None; B. Burroni: None; J. Boussier: None; L. Willems: None; L. Dionet: None; T. Pierre-Louis: None; D. duffy: None; M. Ménager: None; O. Kosmider: None; B. Terrier: AstraZeneca, 2, GlaxoSmithKline, 2, Novartis, 2, Vifor Pharma, 2.

To cite this abstract in AMA style:

Breillat P, Francesco C, Céline P, Templé M, Corneau A, Luka M, Gobeaux C, Outh R, Lazaro E, Le Guenno G, Lifermann F, Berleur M, Le Mene M, Friedrich C, Lenormand C, Weitten T, Guillotin V, Burroni B, Boussier J, Willems L, Dionet L, Pierre-Louis T, duffy D, Ménager M, Kosmider O, Terrier B. Deep Phenotyping Characterization of Peripheral Natural Killer Cells Reveals Impaired Cytotoxicity and Exhaustion During VEXAS Syndrome [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/deep-phenotyping-characterization-of-peripheral-natural-killer-cells-reveals-impaired-cytotoxicity-and-exhaustion-during-vexas-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deep-phenotyping-characterization-of-peripheral-natural-killer-cells-reveals-impaired-cytotoxicity-and-exhaustion-during-vexas-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology